Effect Of Antioxidant And Anti Inflammation on Subchronic Toxicity Administration Of Ganoderma Lucidum Target Organ Kidney in Cardiovascular Diseases

Mochammad Ali Trihartanto,Djanggan Sargowo,Mohammad Aris Widodo,Titin Andri Wihastuti,Teuku Heriansyah,Santy Cintiana Dewi,Ike Dyah Ayu Pambayun,Samsul Bakhri,GregoriusDidikWicaksono S,Novita Qurrota A’ini,Daniwing Putri Sahudi,Sabrinadia Hanareta Hantoko,Januardi Indra Jaya,Kemala Octariny,AhmafiIzzudin Ardhi
DOI: https://doi.org/10.1097/01.hjh.0000469860.92553.b6
IF: 4.9
2015-06-01
Journal of Hypertension
Abstract:Background: Ganodermalucidum was developed as a comprehensive approach for cardiovascular diseases. Efforts to develop polysaccharide peptide(Ganodermalucidum) as antioxidant and antiinflammation in previous studies had proved its ability to significantly reduce the level of MDA, hs-CRP, H2O2, total cholesterol, and foam cell and also increase the level of HDL in Rattusnovergicuswistar strain rats which was givenhigh fat diet. Furthermore, additional study has to be done to understandthe toxicity effect of subchronic administration of polysaccharide peptide (Ganodermalucidum). Objective: To understand the safety profile of renal function in the use of polysaccharide peptide (Ganodermalucidum) through subchronic toxicity test in animals. Methods: Subchronic toxicity test in RattusnovergicusWistar strain rats, with 6 rats/sex/group was given pure solution (freeze dried) of Ganodermalucidum with the dose of 0, 300, 600, 1200 mg/kgBB using feeding tubeonce a day for 90 days. Result: Until the 90th day after administration ofpure extract of Ganodermalucidum (freeze dried) with the dose of 300,600,1200 mg/kgBB in male and female rats, there was no toxic symptoms and did not affect the target organ kidney. The gross pathology and histopathology examination of the kidney showed no morfological and histopathology abnormality finding. Conclusion: There was no toxicity effect to the target organ kidney in subchronic oral administration of polysaccharide peptide(Ganodermalucidum) up to the dose of 1200 mg/kgBB/day.
peripheral vascular disease
What problem does this paper attempt to address?